Sunday, July 8, 2012

Cuba is increasing sales of anti malaria products in Africa




A Cuban company is increasing sales of its mosquito larvicides to fight malaria in Africa, despite cautions by U.N. experts that such products have limited use and are not the most cost-effective method of attacking the disease.

Ghana alone signed a $74 million, two-year deal for a single larvicide program, a Labiofam representative in the West African nation, Hafez Adam Taher, was quoted as saying in a British newspaper report earlier this year.

They are pushing their products by playing on the warm bilateral relations established when Cuba assisted many newly independent African nations in the 1970s.

Malaria is a preventable and curable infectious disease caused by the Plasmodium parasite transmitted by the female Anophelesmosquito. More than 1 million of the 300-500 million cases of malaria each year result in death. Malaria is the leading cause of death for children under age five in sub-Saharan Africa, and a predominant killer of pregnant women and their unborn children. Malaria costs Africa an estimated $12 billion in lost productivity each year.

Malaria control combines the following primary strategies:
Indoor Residual Spraying
Long-Lasting Insecticidal Nets
Artemisinin-based Combination Therapies
Intermittent Preventative Therapy for pregnant women

Malaria settles down in your liver and blood and if not treated right and on time damages kidney and liver.

No comments:

Post a Comment

  • Read this blog in another language